AMD Awareness

A large study performed in Canada analyzed data and found that patients are at higher risk of multiple possible complications after cataract surgery.

The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of the EMA's initial response

Research by investigators at Trinity College in Dublin, Ireland shows how the gene therapy conferred significant protection for retinal ganglion cells

The biosimilar is indicated to improve and maintain visual acuity for patients with neovascular age-related macular degeneration

A novel formulation may prevent blood vessel growth and vascular leakage in the retina

Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea

The drug is a biosimilar for aflibercept 2 mg (Eylea)

The flagship, light-based technology has received approval for applications in the anterior and posterior segments

The approval also grants Outlook Therapeutics an initial 10 years of market exclusivity in the EU for bevacizumab gamma (LYTENAVA)

The agency issued approval for Yesafili, from Biocon Biologics, and Opuviz, from Samsung Bioepis and Biogen

For decoding biomarkers, a multistage system is just the beginning

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March

Antonio Filipe Macedo, OD, MSc, PhD, speaks about his ARVO presentation on vision-related activity difficulties in patients with neovascular age-related macular degeneration

Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care

I-SCREEN will bring together 12 institutions across Europe, including Queen’s University Belfast

The European Commission is expected to make a decision about the application before the end of June

Research indicates smoking increases risk of AMD, cataracts and glaucoma

Physicians explore how other specialties adopt and integrate remote monitoring

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants

The trial will use vision preservation as a primary outcome measure, according to Annexon

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME

The study illustrates efficacy of AVT06 as compared with aflibercept (Eylea) for neovascular age-related macular degeneration

Real-world data from using faricimab to treat neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME)

The study results will help to identify dosing levels for future clinical trials

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD